Antitrust Case against Bristol Myers over Pomalyst Patent Practices Dismissed

A U.S. Federal Judge dismissed a lawsuit by Blue Cross Blue Shield (Plaintiff) accusing Bristol Myers Squibb of unlawfully protecting its monopoly on cancer drug Pomalyst. The Court held that there was no sufficient evidence for Plaintiff’s claim that the company unlawfully delayed the entry of cheaper generic versions of Pomalyst into the market which purportedly led to inflated costs for buyers since at least October 2020.